Literature DB >> 27708971

Low vitamin D status in systemic sclerosis and the impact on disease phenotype.

Laura Groseanu1, Violeta Bojinca1, Tania Gudu2, Ioana Saulescu1, Denisa Predeteanu1, Andra Balanescu1, Florian Berghea1, Daniela Opris1, Andreea Borangiu1, Cosmin Constantinescu1, Magda Negru1, Ruxandra Ionescu1.   

Abstract

OBJECTIVE: Vitamin D has pleiotropic effects including immunomodulatory, cardioprotective, and antifibrotic properties and is thus able to modulate the three main links in scleroderma pathogenesis. The aim of the study was to evaluate the level of vitamin D in patients with systemic sclerosis and to analyze the associations between the concentration of vitamin D and the features of systemic sclerosis.
MATERIAL AND METHODS: Fifty-one consecutive patients were evaluated for visceral involvement, immunological profile, activity, severity scores, and quality of life. The vitamin D status was evaluated by measuring the 25hydroxy-hydroxyvitamin D serum levels.
RESULTS: The mean vitamin D level was 17.06±9.13 ng/dL. Only 9.8% of the patients had optimal vitamin D levels; 66.66% of them had insufficient 25(OH)D levels, while 23.52% had deficient levels. No correlation was found between vitamin D concentration and age, sex, autoantibody profile, extent of skin involvement, or vitamin D supplementation. Vitamin D levels were correlated with the diffusing capacity of the lung for carbon monoxide (p=0.019, r=0.353), diastolic dysfunction (p=0.033, r=-0.318), digital contractures (p=0.036, r=-0.298), and muscle weakness (p=0.015, r=-0.377) and had a trend for negative correlation with pulmonary hypertension (p=0.053, r=-0.29).
CONCLUSION: Low levels of vitamin D are very common in systemic sclerosis. Poor vitamin status seems to be related with a more aggressive disease with multivisceral and severe organ involvement, especially pulmonary and cardiac involvement.

Entities:  

Keywords:  Systemic scleroderma; visceral involvement; vitamin D

Year:  2016        PMID: 27708971      PMCID: PMC5042230          DOI: 10.5152/eurjrheum.2015.0065

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  35 in total

1.  Very low levels of vitamin D in systemic sclerosis patients.

Authors:  Paola Caramaschi; Alessandra Dalla Gassa; Orazio Ruzzenente; Alessandro Volpe; Viviana Ravagnani; Ilaria Tinazzi; Giovanni Barausse; Lisa M Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2010-05-09       Impact factor: 2.980

2.  The HAQ disability index in scleroderma trials.

Authors:  S R Johnson; P Lee
Journal:  Rheumatology (Oxford)       Date:  2004-09       Impact factor: 7.580

Review 3.  Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?

Authors:  Michele Iudici; Gianluca Moroncini; Paola Cipriani; Roberto Giacomelli; Armando Gabrielli; Gabriele Valentini
Journal:  Autoimmun Rev       Date:  2015-02-21       Impact factor: 9.754

4.  The relationship between vitamin D deficiency and pulmonary hypertension.

Authors:  M Demir; U Uyan; S Keçeoçlu; C Demir
Journal:  Prague Med Rep       Date:  2013

5.  Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells.

Authors:  Allan M Ramirez; Cherry Wongtrakool; Teresa Welch; Andreas Steinmeyer; Ulrich Zügel; Jesse Roman
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-17       Impact factor: 4.292

Review 6.  The implication of vitamin D and autoimmunity: a comprehensive review.

Authors:  Chen-Yen Yang; Patrick S C Leung; Iannis E Adamopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

7.  Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat.

Authors:  Michael S K Wong; R Delansorne; Ricky Y K Man; Paul M Vanhoutte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-16       Impact factor: 4.733

8.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

9.  Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor.

Authors:  G Rashid; J Bernheim; J Green; S Benchetrit
Journal:  Eur J Clin Invest       Date:  2008-11       Impact factor: 4.686

10.  Severe pulmonary hypertension: The role of metabolic and endocrine disorders.

Authors:  Harm J Bogaard; Aysar Al Husseini; Laszlo Farkas; Daniela Farkas; Jose Gomez-Arroyo; Antonio Abbate; Norbert F Voelkel
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

View more
  14 in total

1.  Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients.

Authors:  Mehrzad Hajialilo; Parisa Noorabadi; Sepideh Tahsini Tekantapeh; Aida Malek Mahdavi
Journal:  Rheumatol Int       Date:  2017-08-22       Impact factor: 2.631

2.  Vitamin D deficiency and clinical correlations in systemic sclerosis patients: A retrospective analysis for possible future developments.

Authors:  Amelia Chiara Trombetta; Vanessa Smith; Emanuele Gotelli; Massimo Ghio; Sabrina Paolino; Carmen Pizzorni; Amber Vanhaecke; Barbara Ruaro; Alberto Sulli; Maurizio Cutolo
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

Review 3.  Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach.

Authors:  Balazs Odler; Vasile Foris; Anna Gungl; Veronika Müller; Paul M Hassoun; Grazyna Kwapiszewska; Horst Olschewski; Gabor Kovacs
Journal:  Front Physiol       Date:  2018-06-19       Impact factor: 4.566

Review 4.  Role of Vitamin D Beyond the Skeletal Function: A Review of the Molecular and Clinical Studies.

Authors:  Meenakshi Umar; Konduru S Sastry; Aouatef I Chouchane
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

5.  Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.

Authors:  Alexandra-Diana Diaconu; Iustina Ostafie; Alexandr Ceasovschih; Victorița Șorodoc; Cătălina Lionte; Codrina Ancuța; Laurențiu Șorodoc
Journal:  J Immunol Res       Date:  2021-11-29       Impact factor: 4.818

6.  Dualities of the vitamin D in systemic sclerosis: a systematic literature review.

Authors:  Laiana Schneider; Vanessa Hax; Odirlei Monticielo; Tamires Ferri Macedo; Roberta Kern Menna Barreto; Natália Aydos Marcondes; Rafael Chakr
Journal:  Adv Rheumatol       Date:  2021-06-09

Review 7.  Influence of Seasonal Vitamin D Changes on Clinical Manifestations of Rheumatoid Arthritis and Systemic Sclerosis.

Authors:  Maurizio Cutolo; Stefano Soldano; Alberto Sulli; Vanessa Smith; Emanuele Gotelli
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

8.  Evaluation of Serum Vitamin D Levels in Patients with Systemic Sclerosis and Healthy Controls: Results of a Pilot Study.

Authors:  Sarita Gupta; Vikram K Mahajan; Rajinder S Yadav; Karaninder S Mehta; Satya Bhushan; Pushpinder S Chauhan; Ritu Rawat; Vikas Sharma
Journal:  Indian Dermatol Online J       Date:  2018 Jul-Aug

Review 9.  Vitamin D levels in systemic sclerosis patients: a meta-analysis.

Authors:  Lin An; Ming-Hui Sun; Feng Chen; Jin-Ran Li
Journal:  Drug Des Devel Ther       Date:  2017-10-27       Impact factor: 4.162

10.  The effect of vitamin D3 and thyroid hormones on the capillaroscopy-confirmed microangiopathy in pediatric patients with a suspicion of systemic connective tissue disease-a single-center experience with Raynaud phenomenon.

Authors:  Katarzyna Kapten; Krzysztof Orczyk; Elzbieta Smolewska
Journal:  Rheumatol Int       Date:  2021-06-16       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.